019170 - Shinpoong Pharmaceutical Co., Ltd.

019170 Summary

Biopharma

Stock Price & Overview

₩10,010 -90 (-0.89%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩10,010 ≈ US$7 · Market cap ₩0.5tn (≈ $375m)

019170 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	234.7	221.1	200.2	209.3	189.2	197.8	189.7	187.4	185.0	194.1	196.0
Cost of Revenue	132.0	139.3	120.0	131.3	111.8	121.2	113.5	111.5	104.5	105.6	108.3
Gross Profit	102.7	81.8	80.3	78.0	77.4	76.5	76.2	75.9	80.5	88.5	87.7
Selling, General & Administrative	88.4	102.3	127.7	112.0	91.7	68.7	70.6	68.1	72.3	80.9	83.7
Operating Income	14.3	-20.5	-47.4	-34.0	-14.3	7.8	5.6	7.8	8.1	7.6	4.0
Finance Income	3.1	6.7	4.8	3.6	3.4	3.3	2.7	2.2	0.5	0.8	0.4
Finance Costs	9.1	4.7	4.8	3.3	1.1	6.3	4.7	4.7	5.2	5.7	7.0
Pretax Income	8.5	-14.6	-53.4	-34.8	-9.0	8.3	7.1	5.2	2.0	-5.6	1.9
Income Tax Expense	0.1	0.8	3.8	0.5	2.5	3.3	1.7	2.4	0.8	14.9	0.7
Net Income	8.4	-15.4	-57.3	-35.3	-11.5	5.0	5.4	2.8	1.3	-20.5	1.2
Total Comprehensive Income	10.5	-12.7	-60.0	-29.6	-14.6	6.4	1.7	-1.5	-2.6	-20.0	5.1

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	352.5	342.1	350.1	361.5	398.3	492.9	385.9	386.7	391.4	418.1	414.3
Current Assets	206.7	189.3	198.9	196.5	233.0	338.6	225.0	230.4	219.6	237.4	222.4
Cash & Cash Equivalents	47.4	42.0	43.8	41.7	27.6	55.8	23.4	37.2	19.4	16.1	12.7
Inventories	58.5	55.4	53.9	46.9	47.7	49.1	49.0	44.9	46.9	42.2	45.4
Trade Receivables	72.5	70.2	73.7	82.3	81.9	88.7	99.4	109.1	124.0	144.4	152.8
Non-current Assets	145.7	152.8	151.1	165.0	165.4	154.3	160.9	156.3	171.8	180.7	191.9
Property, Plant & Equipment	108.7	115.4	118.6	113.8	116.9	124.2	130.9	130.5	138.2	144.3	152.2
Intangible Assets	5.1	5.0	5.8	6.9	9.0	8.1	8.9	7.1	8.8	11.3	12.2
Total Liabilities	81.7	84.0	79.3	30.8	38.0	112.8	171.0	173.5	175.5	199.6	215.9
Current Liabilities	66.9	75.8	76.4	27.2	28.6	83.3	134.0	146.2	139.1	167.0	184.2
Non-current Liabilities	14.8	8.2	2.9	3.6	9.5	29.5	37.0	27.3	36.4	32.6	31.6
Total Equity	270.7	258.1	270.8	330.8	360.3	380.1	214.9	213.2	215.9	218.5	198.4
Share Capital	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6	23.7
Retained Earnings	50.8	38.9	55.3	115.8	144.9	162.4	152.2	149.4	149.0	148.2	165.8

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	17.3	-15.2	-24.8	-26.4	-71.0	20.1	19.4	32.1	10.1	19.0	9.9
Cash from Investing Activities	-14.7	5.6	-16.3	43.2	49.0	-95.0	-30.7	-10.3	2.0	-21.2	-0.1
Purchase of Property, Plant & Equipment	3.5	5.6	14.9	5.3	4.4	2.7	12.1	1.8	3.1	1.4	1.9
Cash from Financing Activities	3.7	6.2	43.2	-1.9	-6.4	108.7	-2.5	-4.2	-8.5	5.5	-3.2
Dividends Paid	—	—	—	—	5.2	—	—	—	—	0.0	2.1
Net Change in Cash	5.4	-1.8	2.1	14.1	-28.2	32.4	-13.8	17.7	3.3	3.4	6.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	63.9	54.5	58.0	62.6	58.6	55.4	55.3	55.8	56.0	54.0
Cost of Revenue	36.9	33.1	33.0	33.9	31.3	33.7	35.9	33.6	35.7	34.1
Gross Profit	27.0	21.4	25.0	28.7	27.3	21.7	19.4	22.2	20.3	19.9
Selling, General & Administrative	35.0	21.8	21.1	21.5	22.4	23.4	31.5	22.4	25.0	23.4
Operating Income	-8.0	-0.4	3.9	7.2	4.9	-1.8	-12.1	-0.2	-4.7	-3.5
Finance Income	1.3	2.6	0.7	0.6	0.2	1.7	3.9	0.4	1.0	1.3
Finance Costs	1.3	1.7	4.3	0.6	2.8	1.4	1.8	0.3	1.4	1.2
Pretax Income	-8.0	0.4	0.3	7.3	2.3	-1.5	-10.0	0.0	-1.3	-3.4
Income Tax Expense	-0.0	0.1	-0.1	0.8	0.4	-0.2	2.7	-0.1	-1.2	-0.8
Net Income	-8.0	0.4	0.5	6.4	2.8	-1.3	-12.7	-0.1	-0.0	-2.6
Total Comprehensive Income	-14.2	-8.0	4.4	6.9	0.7	-1.4	-10.1	-0.5	0.1	-2.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	366.5	371.9	352.5	341.6	337.6	336.9	342.1	337.5	340.8	345.8
Current Assets	212.1	209.1	206.7	194.6	189.1	186.6	189.3	193.8	194.3	196.0
Cash & Cash Equivalents	48.1	52.1	47.4	39.7	38.4	41.2	42.0	50.1	48.0	47.3
Inventories	62.1	59.1	58.5	59.3	59.6	56.6	55.4	54.4	53.8	57.9
Trade Receivables	72.8	67.5	72.5	71.5	69.6	67.0	70.2	70.8	73.3	72.8
Non-current Assets	154.4	162.8	145.7	147.0	148.6	150.3	152.8	143.7	146.5	149.8
Property, Plant & Equipment	106.2	107.0	108.7	110.8	111.5	113.9	115.4	115.7	116.5	118.4
Intangible Assets	5.2	4.9	5.1	5.1	5.2	4.9	5.0	5.2	5.5	5.5
Total Liabilities	88.5	79.6	81.7	77.4	80.3	80.3	84.0	69.3	72.2	77.2
Current Liabilities	74.3	65.4	66.9	71.0	73.1	72.1	75.8	66.4	69.4	74.3
Non-current Liabilities	14.2	14.2	14.8	6.4	7.2	8.2	8.2	2.9	2.8	2.9
Total Equity	278.0	292.3	270.7	264.2	257.3	256.7	258.1	268.2	268.7	268.6
Share Capital	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6	27.6
Retained Earnings	41.6	49.6	50.8	47.3	40.9	37.7	38.9	52.6	52.7	52.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-1.1	6.4	3.4	8.9	4.7	0.2	-16.0	6.5	-5.6	-0.1
Cash from Investing Activities	-0.8	-0.9	-4.9	-4.6	-4.7	-0.5	-3.9	-2.3	7.9	4.0
Purchase of Property, Plant & Equipment	1.4	0.6	0.7	1.4	0.4	1.0	1.7	1.5	0.3	2.2
Cash from Financing Activities	-2.2	-1.9	9.5	-3.2	-1.3	-1.3	10.7	-2.8	-1.3	-0.4
Net Change in Cash	-4.1	4.7	7.7	1.3	-2.8	-0.8	-8.1	2.2	0.7	3.5

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

019170 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	234.7	+6.1%	+3.9%	+3.5%	+1.8%
Operating income	14.3	—	—	+12.7%	+13.7%
Net income	8.4	—	—	+10.7%	+21.5%
EPS	₩160	—	—	+10.7%	+21.5%
Operating cash flow	17.3	—	—	-3.0%	+5.7%
Shareholders' equity	270.7	+4.9%	-6.5%	-6.6%	+3.2%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

019170 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	43.7%	37.0%	40.1%	37.3%	40.9%	38.7%
Operating margin	6.1%	-9.3%	-23.7%	-16.3%	-7.6%	4.0%
Net margin	3.6%	-7.0%	-28.6%	-16.9%	-6.1%	2.6%
Return on equity	3.2%	-5.8%	-19.0%	-10.2%	-3.1%	1.7%
Return on assets	2.4%	-4.4%	-16.1%	-9.3%	-2.6%	1.1%
Operating cash flow / revenue	7.4%	-6.9%	-12.4%	-12.6%	-37.5%	10.1%
Capex / revenue	1.5%	2.5%	7.4%	2.5%	2.3%	1.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 019170

Symbol	Last Price
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
317450Myungin Pharm	₩44,650 +0.0%
001060JW Pharmaceutical	₩27,500 +1.3%
456160G2GBIO, Inc.	₩37,950 +5.7%
358570GI Innovation, Inc.	₩8,090 +6.2%
086900Medy-Tox, Inc.	₩69,600 +0.4%
397030April Bio Co., Ltd.	₩17,800 +6.1%
249420Ildong Pharm	₩15,030 -0.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.